Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks (NCT00418145), a randomized phase 3 study. The primary outcome is Expanded Disability Status Scale (EDSS) Mean Recovery From Day 0 to Day 28..

2. Clinical Question

In practical statistical terms, the intended question was whether the measured recovery differed between the oral and intravenous treatment groups over the stated assessment period. The registry identifies a randomized, blinded, multi-center study and lists a parallel-group design. These features describe the planned comparison, but they do not establish what the results were. The record lists enrollment of 16, without arm-specific enrollment or participant-flow information.

Secondary questions concerned clinical parameters of the Multiple Sclerosis Functional Composite Scale, relapse frequency over time up to one year, and improvement using targeted neurological deficits. The registry lists four outcome measures in total, but does not provide results for these secondary outcomes either. Consequently, the clinical question can be described from the stated aims, while the relative outcome patterns and their precision cannot be assessed from the registry record.

3. Trial Design

The study is titled “Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks,” with the official title “Oral Megadose Corticosteroid Therapy of Acute Exacerbations of Multiple Sclerosis (OMEGA).” It is listed as a Phase 3, randomized, quadruple-masked, parallel study. The brief summary describes it as a randomized, blinded, multi-center comparison of oral and intravenous methylprednisolone for acute exacerbations of relapsing forms of multiple sclerosis.

The oral arm is described as megadose oral methylprednisolone, 1400 mg qd/5 days. The intravenous arm is described as IV methylprednisolone, 1000 mg/qd/5 days. The study summary calls these equivalent doses. The registry record does not explain the basis for that description, nor does it detail the masking procedures, allocation process, treatment adherence assessment, or the number of sites.

Enrollment is listed as 16. This is the recorded enrollment, not evidence that 16 participants completed follow-up or contributed to every outcome. The number assigned to each arm, withdrawals, exclusions from analyses, and analysis populations are not reported in the registry record. The listed start is 2003-09 and primary completion is 2013-10. The status is terminated; the registry record does not report the reason for termination.

The primary outcome is named as mean EDSS recovery from Day 0 to Day 28, with a timeframe of Day 28 and Day 90. Secondary outcomes include MSFC clinical parameters, relapse frequency over time up to one year, and targeted neurological deficits. Although the registry lists four outcome measures, it reports zero analyses and says there is no data analysis for the study. It also states that the data are no longer accessible. The planned design therefore gives context for the intended comparison, but cannot substitute for outcome estimates or details of the analysis actually conducted.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Data is also no longer accessible. Data was with biostatistician who no longer has data.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: 16 participants were enrolled into the study. Data not available separated by arm. Data is also no longer accessible. Data was with biostatistician who no longer has data.

6. Primary Endpoint

The registry lists the primary outcome as Expanded Disability Status Scale (EDSS) Mean Recovery From Day 0 to Day 28., measured over Day 28 and Day 90.

The named primary endpoint is Expanded Disability Status Scale (EDSS) mean recovery from Day 0 to Day 28. The registry gives “Day 28 and Day 90” as the timeframe. It does not define the exact recovery calculation, identify the value used as the baseline, or explain how the Day 90 assessment fits into an endpoint named for Day 28. Those details are not reported in the registry record.

In general, a prespecified primary endpoint gives a trial one principal outcome on which to focus its main comparison. A defined measure and assessment time help readers understand what the treatment groups are being compared on. A change or recovery measure can describe how an outcome differs from an earlier assessment, but interpretation depends on a clear definition of the measure, its direction, the assessment schedule, and the analysis population. The registry record supplies the EDSS endpoint name and timeframe, but does not provide these analytic details.

The endpoint could have been used to compare mean recovery between the oral and intravenous groups, but no group means, between-group estimate, uncertainty interval, or test result is reported. The record explicitly states that there is no data analysis for the study. Accordingly, it is possible to identify the intended primary measure, but not to quantify the observed recovery or compare its precision across treatments from the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry identifies the study as randomized, quadruple-masked, and parallel. These are design descriptions, not outcome findings. Randomization generally assigns participants to groups by a chance-based process. When implemented appropriately, it can reduce systematic differences in prognostic factors between groups on average. It does not guarantee that groups will be balanced in a small study, and it cannot by itself address missing outcome data or incomplete reporting. The record does not describe the randomization sequence, allocation concealment, or arm-specific baseline characteristics.

What does masking mean for interpretation?

Masking generally means that specified people involved in a trial are not told which treatment assignment applies. It can reduce the influence of treatment knowledge on care, outcome assessment, or reporting. The registry labels this study quadruple-masked, but does not identify which groups of people were masked or how masking was maintained. The label therefore describes the registered design without allowing an assessment of its implementation.

What would a treatment estimate represent?

For a continuous outcome such as a mean recovery measure, a group comparison would ordinarily be expressed as a difference in means or another defined contrast. That estimate would summarize the observed separation between the groups under a specified analysis. A confidence interval would describe the uncertainty associated with the estimate under the statistical method used. A narrow interval generally indicates greater precision than a wide interval, while neither interval width nor statistical significance alone establishes clinical importance. The registry record reports no group means, treatment contrast, confidence interval, or test result, so none of these quantities can be interpreted for this study.

Interpretation also depends on the endpoint definition. The registry names mean EDSS recovery from Day 0 to Day 28 and gives Day 28 and Day 90 as the timeframe. It does not specify whether recovery was calculated as a change score, how the two assessment times were incorporated, or which analysis model was intended. Different valid analysis choices can answer different questions. Because the analysis is not reported, the intended estimand—the precise treatment effect the analysis was meant to estimate—is also not described.

What do the planning assumptions tell readers?

The registry describes a planning illustration using a two-sided significance level of 0.05, equal allocation between arms, and a normal approximation. It says the effect to detect is a stated fraction of the observed effect. Such assumptions can be used, in general, to illustrate how a hypothetical sample size relates to an assumed effect and analysis approach. They do not describe the trial’s actual allocation or prove that the study was designed with those assumptions. The record labels the exercise a planning illustration, not the trial’s own design. Since the observed effect and resulting sample-size values are not reported, the illustration cannot be interpreted as a numerical evaluation of this study. It is not observed power.

In general, power is a design concept describing the chance that a study will detect a specified effect under stated assumptions. After results are observed, a sample-size calculation based on the observed effect is not a substitute for reporting the estimate and its uncertainty. For this record, there is no reported outcome effect on which to base such an interpretation. The registry does not report a sample-size justification, target enrollment, or interim analysis plan.

Why does the analysis population matter?

A treatment comparison can depend on which randomized participants are included and how their outcomes are handled. An analysis of all randomized participants, an analysis limited to those who followed treatment, and an analysis limited to participants with measured outcomes can answer different questions and may be subject to different biases. These are general distinctions; the registry does not report which population was used or intended. It lists enrollment of 16 but does not give assignment counts, follow-up counts, exclusions, or reasons for missing data.

For a continuous endpoint, missing measurements can affect group means and treatment contrasts. Statistical approaches to missingness rely on assumptions about why data are missing; those assumptions need to be described and examined where possible. The record says the data are no longer accessible and supplies no missing-data method. It is therefore not possible to determine whether outcome data were complete, how missing observations were addressed, or how sensitive the result might be to those choices.

The secondary outcomes include relapse frequency over time, an outcome that may involve event counts or timing. In general, count data can show over-dispersion when their variability exceeds what a simple count model assumes, and time-to-event methods account for event timing and censoring. These are general methodological considerations, not methods reported as used in this study. The registry provides no analysis details for relapse frequency or any other secondary outcome. No statistical method should be attributed to the trial beyond the design labels and planning assumptions explicitly recorded.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists one primary outcome and secondary outcomes concerning MSFC clinical parameters, relapse frequency over time up to one year, and targeted neurological deficits. It also lists four outcome measures in total. Testing or interpreting several outcomes can raise multiplicity concerns: in general, the more comparisons considered, the greater the chance that at least one result appears notable by chance if no adjustment or interpretive plan is used. The registry record does not report a multiplicity adjustment, hierarchy among secondary outcomes, or a prespecified approach to interpreting multiple results. Since no analyses or results are reported, the impact of multiplicity cannot be assessed.

Missing-data information is also not reported. The record says the data are no longer accessible, but does not state how many participants had outcome measurements at Day 28 or Day 90, whether follow-up was complete, or why any data might be absent. The number enrolled is 16, but enrollment alone does not show how many participants were analyzed for any endpoint. No imputation method, sensitivity analysis, or missingness assumption is described in the registry record.

The analysis population is not reported. There is no description of whether the intended analysis included all randomized participants or used another population. Arm-specific assignment numbers, participant flow, and exclusions are also absent. These omissions matter because the treatment comparison can depend on who is included and how incomplete observations are handled. Without these details, neither the handling of multiplicity nor the robustness of an analysis to missing data can be evaluated.

11. What the Result Does, and Does Not, Mean

The record shows that investigators registered a randomized, blinded, parallel comparison of oral and intravenous methylprednisolone for acute exacerbations of relapsing forms of multiple sclerosis. It gives the intended primary endpoint, lists secondary outcomes, records enrollment of 16, and identifies the study status as terminated. It also says there is no data analysis for the study and that the data are no longer accessible.

Those details describe the study, not the comparative outcome. They do not show whether mean EDSS recovery differed between treatment groups, how large any difference might have been, or how precisely it was estimated. They do not establish that the treatments had the same outcomes or that one treatment had better outcomes. No result is reported for the secondary outcomes either.

The registry’s zero adverse-event counts do not establish that no adverse events occurred. Without information about follow-up, collection, and reporting, the counts cannot be interpreted as a complete safety comparison. Likewise, the planning assumptions described in the record do not constitute a result, and they cannot replace an outcome estimate or confidence interval.

In general, a randomized design can support a fair comparison when its procedures and analysis are appropriately implemented and reported. The registry record does not provide enough detail to evaluate those procedures, the analysis population, missing data, or the actual outcome analysis. The appropriate interpretation is therefore limited: the intended comparison is documented, but its results and statistical precision are not reported in the registry record.

12. Why This Trial Matters Statistically

This trial matters statistically as an example of the difference between a registered design and an interpretable result. The record describes randomization, quadruple masking, a parallel structure, a primary endpoint, and secondary outcomes. Those details indicate what investigators intended to study. But the record also states that no data analysis is available and that the data are no longer accessible. Without estimates and their uncertainty, readers cannot evaluate the comparative findings.

That distinction is important for any clinical trial. A design label does not show that the design was implemented as planned, while an endpoint name does not reveal the size or precision of an effect. Enrollment of 16 gives context for the record, but without arm-specific counts, participant flow, and analyzed outcomes it cannot explain how much information was available for any comparison. Likewise, an absence of reported results should not be mistaken for a finding of no difference.

The record also illustrates why complete reporting matters beyond the primary endpoint. It lists secondary clinical, relapse, and neurological outcomes, but does not report analyses for them. It does not explain missing data or analysis populations, and its zero adverse-event counts lack the context needed for interpretation. These gaps prevent assessment of both the outcome findings and the methods used to obtain them.

For statistical readers, the central lesson is restraint: state the registered question and design, distinguish planning assumptions from results, and avoid converting missing analyses into evidence for or against a treatment effect. In this case, the record documents the intended comparison but not its answer.

13. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The most consequential limitation is explicit in the registry record: there is no data analysis for the study, and the data are described as no longer accessible. Therefore, the primary outcome has no reported group estimates or comparative analysis. No confidence intervals, test results, or numerical findings are available for the primary or secondary outcomes.

The record lists enrollment of 16 but does not report how many participants were randomized to each group, completed assessments, or contributed to each analysis. The reason for termination is not reported in the registry record. Nor does the record explain why data became inaccessible, when that occurred, or whether any analyses were completed outside the registry.

The endpoint description leaves details unresolved. It names mean EDSS recovery from Day 0 to Day 28, while the timeframe includes Day 28 and Day 90. The calculation of recovery and the relationship between the two assessment times are not reported. Detailed eligibility criteria, baseline characteristics, site count, masking procedures, adherence, allocation concealment, and the analysis plan are also not reported in the registry record.

The registry lists zero adverse-event counts in both groups, but does not provide the collection and follow-up context required to interpret those counts. It does not report outcome completeness, missing-data handling, analysis populations, multiplicity procedures, or sensitivity analyses. These limitations prevent evaluation of the study’s results, precision, and robustness. They are limitations of the available registry record and do not establish what may or may not exist outside it.

14. Related Tutorials

15. Related Statistical Calculators

16. Sources

• ClinicalTrials.gov: Study to Evaluate Intravenous and Oral Steroids for Multiple Sclerosis Attacks — NCT00418145.
• Registry record last updated 2017-05-18; status last verified 2017-04.
• Results first posted 2017-05-18.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

17. Record Summary

NCT00418145 is registered as a Phase 3 randomized, quadruple-masked, parallel study of oral and intravenous methylprednisolone for acute exacerbations of relapsing forms of multiple sclerosis. It lists enrollment of 16 and status as terminated. The registry gives a start of 2003-09 and primary completion of 2013-10.

The oral arm is described as megadose oral methylprednisolone, 1400 mg qd/5 days; the IV arm is described as 1000 mg/qd/5 days. The primary outcome is mean EDSS recovery from Day 0 to Day 28, with a timeframe of Day 28 and Day 90. Secondary outcomes include MSFC clinical parameters, relapse frequency up to one year, and targeted neurological deficits.

The record states that no data analysis is available and that the data are no longer accessible. No efficacy results, analysis methods, or detailed participant-flow information are reported. Registry adverse-event counts are zero in both groups, but their completeness and context are not described.